A new analysis found potential gene therapies for blood disorders like hemophilia, beta thalassemia, and sickle cell disease hold promise in dramatically reducing existing treatment burdens for patients, which could result in as much as $730,000 in savings to the health care system and increase a patient’s income by as much as $9,500 in the year following treatment.
Blood disorders often require lifelong treatment involving routine drug infusions or blood transfusions. They can also be associated with frequent visits to physician offices, infusion centers or even the emergency room. Patients with these disorders often experience debilitating pain, disability, reduced life expectancy and quality of life.
Gene therapies currently in development hold tremendous promise to completely transform the treatment paradigm for these patients, not only improving quality of life but leading to significant savings to the health care system and patients.
Today, there are more than 500 medicines in development for disorders of the blood, including many gene therapies. While many gene therapies are administered just one time with long-lasting or even potentially curative effects, the full value they provide to patients, caregivers and the entire health care system may only be realized over the lifetime of the patient. Addressing the unique challenges presented by these groundbreaking therapies requires a rethinking of the way we pay for medicines to account for the long-term value these therapies provide.
Learn more by viewing the report and fact sheets here.
Katie Koziara
Katie Koziara is Senior Director of public affairs at PhRMA focusing on the organization’s executive visibility work and media relations strategy. She previously ran the social media strategy for a D.C.-based non-profit working on federal management and leadership issues. Katie earned her B.A. in Public Policy from the University of Michigan’s Ford School and is currently earning her M.A. in Fiction Writing from Johns Hopkins University.
Katie Koziara
World Sickle Cell Day: Recognizing the promise of gene therapy
New report shows promising pipeline for cell and gene therapies, but access challenges persist
The Patient Perspective: Vaccines
New Report: Tackling chronic conditions with preventive treatment
New Report: Vaccines continue to drive improved health outcomes
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
New Report: 1,600 cancer treatments and vaccines in clinical development
Incomplete evaluations undermine patient access to transformational medicine
Watch: New video series spotlights advances in biopharmaceutical science
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
Support for continued progress is critical for pediatric drug development
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
State policymakers can protect American innovation and help Americans live longer, healthier lives
Recognizing National Glaucoma Awareness Month
New Report More than 160 medicines in development for mental illness
ICYMI: Cancer death rate continues to decline due to treatment advances
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
New Report: Nearly 800 medicines in development to treat chronic conditions
Recognizing National Sickle Cell Awareness Month
Potential gene therapies bring hope to patients with sickle cell disease
ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free
Report: More than 500 medicines in development to treat disorders of the blood
Report: More than 600 medicines in development for diseases affecting women
New Report: Nearly 800 new medicines in development to treat rare diseases
Guest post: Continued research and development is critical for ALS patients and families
New report shows more than 260 medicines in development to fight neurodegenerative diseases
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections
Report: More than 1,300 medicines and vaccines in development to help fight cancer
New report shows nearly 260 vaccines in development, including dozens for COVID-19
Nearly 400 cell and gene therapies in development to target a broad range of diseases
Nearly 140 medicines in development to treat mental illness
New report shows more than 160 medicines in development for diabetes and related conditions
New report shows nearly 20 innovative medicines in development for sickle cell disease
130 medicines in development for asthma, allergies and other respiratory diseases
130 medicines in development for asthma, allergies and other respiratory diseases
New report shows nearly 300 cell and gene therapies in development
World AIDS Day 2018: Hope for the future
New report shows more than 300 skin disease medicines in development
New report details the setbacks and challenges to Alzheimer’s research
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
A new era in Alzheimer’s innovation
New report shows over 500 medicines in development for neurological disorders
Guest post: Advancing healthy hearts for patients
Rare Disease Day: Unmet need inspires innovation
New report shows 200 medicines in development for heart disease and stroke
Record number of personalized medicines approved in 2017
World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation
2017 Research & Hope Awards honor innovators in mental health
Medicare Monday: Strengthening access to vaccines for seniors
Finding cures for incurable diseases
New report portrays flourishing pipeline
More than 50 medicines and vaccines in development for HIV infection, treatment and prevention
Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines
More than 240 immuno-oncology treatments in development to fight cancer
ICYMI: The New Era of Medicine initiative spotlights genomics in NYC
Significant progress fighting cancer: Death rate has dropped 25 percent
3 things to know about 2016 drug approvals
Gene therapies can reduce treatment burden and costs for patients with blood disorders
Medicines in Development
Personalized Medicine
Cell and Gene Therapy
Gene therapies can reduce treatment burden and costs for patients with blood disorders
Gene therapies can reduce treatment burden and costs for patients with blood disorders